Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 646 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: proteolytic enzymes Clear all
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

NCT04715048
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA, Onabotulinum toxin A
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

NCT03675685
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
CCH (collagenase clostridium histolyticum)
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Not applicable Interventional Results available

Negative Pressure Wound Therapy With Instillation of Saline Solution Versus Collagenase Ointment in Full-thickness Wounds

NCT03722485
View directory record Official record
Conditions
Wounds and Injuries, Wound Healing, Granulation Tissue
Interventions
Negative Pressure Therapy w/ instillation and dwell (NPWTi-d), Collagenase Ointment
Device · Biological
Lead sponsor
KCI USA, Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 20, 2026, 4:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Simulated Conversation Training for Mental Healthcare Providers to Improve Care for Transgender and Gender Nonconforming Individuals

NCT04820088
View directory record Official record
Conditions
Gender Affirming Communication Skills
Interventions
Computer based role play trianing
Other
Lead sponsor
SIMmersion, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Columbia, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

NCT03785678
View directory record Official record
Conditions
THROMBOLYSIS
Interventions
Tenecteplase, Placebo
Biological · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
94
States / cities
Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

NCT06721520
View directory record Official record
Conditions
Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia, Pylorus Dysfunction, Esophageal Dysmotility
Interventions
Botulinum Toxin A (Botox ), Pyloromyotomy
Biological · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction

NCT00001298
View directory record Official record
Conditions
Kidney Diseases
Interventions
carboxypeptidase-G2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 4:03 AM EDT
Completed No phase listed Observational

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

NCT04215536
View directory record Official record
Conditions
Diabetes
Interventions
Empagliflozin, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
103,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Results available

Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis

NCT00813904
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
rThrombin, 1000 IU/mL
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tuscon, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Lower Limb Spasticity Study

NCT01249404
View directory record Official record
Conditions
Leg Spasticity
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment

NCT03799484
View directory record Official record
Conditions
Forehead Rhytides, Forehead Wrinkles
Interventions
Botulinum toxin type A, 2.5% lidocaine/2.5% prilocaine, petrolatum ointment
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 20, 2026, 4:03 AM EDT
Not listed Phase 4 Interventional

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Xiaflex® 0.58 mg
Drug
Lead sponsor
Manhattan Medical Research Practice, PLLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

NCT05960578
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Apalutamide, Biopsy, Biospecimen Collection, Computed Tomography, Golimumab, Magnetic Resonance Imaging, PSMA PET Scan, Bone Scan
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01224015
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair

NCT02247193
View directory record Official record
Conditions
Cleft Lip, Scarring, Cleft Palate
Interventions
Botulinum Toxin Type A, Normal Saline Injection
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 6 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

NCT02191579
View directory record Official record
Conditions
Migraine Disorders
Interventions
onabotulinumtoxinA, Topiramate
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Encinitas, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 4 Interventional

OnabotulinumtoxinA for Trigeminal Neuralgia

NCT06216886
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
OnabotulinumtoxinA 100 UNT [Botox], Sodium Chloride 0.9% for Injection, Preservative Free
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Results available

Assess the Penumbra System in the Treatment of Acute Stroke

NCT01429350
View directory record Official record
Conditions
Ischemic Stroke
Interventions
intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 20, 2026, 4:03 AM EDT
Terminated No phase listed Observational

Improving Patient Access to Stroke Therapy Study

NCT01870492
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack
Interventions
Activase, Endovascular therapy
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Pea Hull Fibre Supplementation

NCT02778230
View directory record Official record
Conditions
Healthy
Interventions
Pea Fiber, Control
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 20, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 4:03 AM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 20, 2026, 4:03 AM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 4:03 AM EDT